Known Alzheimer's disease genes account for only 30% of genetic activity of the disease. With 70% of the genetic component of Alzheimer's unknown, not even the best efforts can develop effective therapies to slow, stop or reverse the disease. Cure Alzheimer's Fund is going to the heart of this problem with the Alzheimer's Genome Project Intiative.
 
A+ | A- | Reset
Charles Glabe, Ph.D. Print
Charles Glabe, PhDUniversity of California at Irvine
Professor, Molecular Biology and Biochemistry, School of Biological Sciences.

Dr. Glabe's research program is focused on amyloid structure and aggregation, in particular beta-amyloid, which is the key pathogenic hallmark of Alzheimer's disease. Dr. Glabe made the seminal discovery that protein components of amyloid share a common structure that is recognized by a conformation-specific antibody. This discovery indicates that amyloids likely share a common primary mechanism of pathogenesis in disease.

 
< Prev   Next >